From first-in-class oncology agents to next-generation vaccines, our portfolio represents decades of rigorous science translated into life-changing treatments.
A first-in-class KRASG12C inhibitor demonstrating unprecedented response rates in non-small cell lung cancer patients who have progressed on prior therapy. Phase III data shows a 58% objective response rate versus 14% for standard of care.
First-in-class KRASG12C inhibitor for NSCLC and colorectal carcinoma. 58% ORR in Phase III trial.
Anti-PD-L1 monoclonal antibody approved for metastatic triple-negative breast cancer and bladder carcinoma.
HER2-targeted ADC demonstrating superior efficacy in gastric and breast cancers with improved tolerability profile.
Third-generation statin with superior LDL reduction (54%) and a favourable myopathy profile. Standard of care in 48 countries.
SGLT2 inhibitor with demonstrated 28% reduction in cardiovascular death and hospitalisation in heart failure with reduced ejection fraction.
Disease-modifying therapy for relapsing-remitting MS. Reduces annualised relapse rate by 62% and slows brain atrophy on MRI.
Neuroprotective agent targeting alpha-synuclein aggregation in Parkinson's disease, aiming to modify disease progression rather than manage symptoms.
Broad-spectrum antiviral active against influenza A/B, RSV, and emerging RNA viruses. Reduces viral load below detection within 72 hours.
Recombinant enzyme replacement for Pompe disease. Demonstrated 44% improvement in 6-minute walk test in pivotal trial.
mRNA vaccine providing 89% protection against severe RSV disease in adults 60+. Approved in 34 countries following accelerated review.
Healthcare professionals and patients can report adverse events 24/7 at safety@veridianpharma.com or call +41 61 800 4299.
Full prescribing information, SmPCs, and patient information leaflets are available on request. Contact your local Veridian representative.
Our global pharmacovigilance programme continuously monitors the safety profile of all marketed products across 120+ countries.